Form 4: Repligen Director Sells Shares Under 10b5-1 Plan

Repligen Director Karen A Dawes sold 275 shares of common stock at $161 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Karen A Dawes, a Director at Repligen Corporation (RGEN), reported a sale of common stock.
• The transaction involved the disposition of 275 shares of common stock.
• The shares were sold at a price of $161 per share.
• The sale occurred on December 17, 2025.
• Following this transaction, Karen A Dawes beneficially owns 91,821 shares of Repligen common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the transaction was conducted under a pre-arranged Rule 10b5-1 plan, which suggests it was a scheduled event rather than a reaction to new company developments. The number of shares sold (275) is also relatively small.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not a reaction to recent non-public information, which can mitigate concerns about opportunistic insider selling.

Negatives

• A director's sale of shares, even if pre-planned, reduces their direct ownership stake in the company.

Future Outlook

na

Industry Context

This filing is a standard disclosure of an insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in a director's direct ownership, which is generally a neutral event given the pre-planned nature and small volume.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled sale of a small number of shares by a director under a Rule 10b5-1 plan. Such a transaction typically does not provide sufficient new information to warrant a change in investment recommendation. Investors should continue to evaluate Repligen based on its fundamental financial performance, strategic initiatives, and broader market conditions, rather than this isolated insider transaction.

Keywords

Repligen, RGEN, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan